Serum ALCAM is a potential novel non-invasive marker for predicting the progression of IgA nephropathy.

ABSTRACT:

Background

Activated leukocyte cell adhesion molecule (ALCAM) serves as an important effector that activates and traffics lymphocytes into tissues. The expression and role of ALCAM in IgA nephropathy (IgAN) remain unclear. Here, we aim to evaluate the expression and effect of ALCAM in IgAN patients.

Methods

We performed a prospective study including 71 IgAN patients, and 41 controls. Serum and uALCAM levels were evaluated. Renal expression of ALCAM and its ligand S100B were measured. The correlation of serum ALCAM with clinical data, renal pathology, and prognosis was analyzed. Cox regression analysis was conducted to identify independent factors associated with prognosis. Kaplan-Meier survival analysis was performed to explore the role of serum ALCAM.

Results

Circula

SUBMITTER: Luo Z 

PROVIDER: S-EPMC12750689 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature